Generalized anxiety disorder
Therapeutic area
Psychiatry
Rare disease
No
- Definition
- An anxiety disorder characterized by excessive and difficult-to-control worry about a number of life situations. The worry is accompanied by restlessness, fatigue, inability to concentrate, irritability, muscle tension, and/or sleep disturbance and lasts for at least 6 months.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Generalized anxiety disorder
- Therapeutic area
- Psychiatry
- generalized anxiety disorder
- GAD
- Severity
- Mild
- Neurology
- Psychiatry
- MONDO ID
- MONDO:0001942
- Parent condition
- MONDO:0005618
Related records
Broader conditions (10)
- Anxiety disorder
- Brain disorder
- Central nervous system disorder
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Human disease
- Mental disorder
- Nervous system disorder
- Psychiatric disorder
Trials (513)
- 6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)
- 6-Session Treatment for Generalized Anxiety Disorder
- A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder
- A 10-Week Efficacy and Safety Study for of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
- A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
- A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
- A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity
- A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
- A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
- A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
- A Clinical Trial to Study the Effects of Sensoril® for Patients With Generalized Anxiety Disorder
- A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients
- A Comparison Between Cognitive, Behavioral, and Cognitive-Behavioral Therapy for Generalized Anxiety Disorder
- A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms
- A Dose-Response Safety Study of ENX-102 in Patients With GAD
- A Feasibility Study of Group Metacognitive Therapy Versus Mindfulness Meditation Therapy
- A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder
Approved drugs (5)
- Alprazolam
- Buspirone hydrochloride
- Escitalopram oxalate
- Pregabalin
- Venlafaxine hydrochloride
Drugs in development (24)
- Buspirone Phase 3
- Cariprazine Phase 2
- Chamomile Phase 3
- Cimetidine Phase 1
- Darigabat Phase 2
- Duloxetine Phase 3
- Escitalopram Phase 3
- Eszopiclone Phase 2
- Fluvoxamine Phase 3
- Glutamine Phase 2
- Imagabalin Phase 3
- Metformin Phase 1
- MK-0777 Phase 2
- Ocinaplon Phase 3
- Paroxetine Phase 3
- Pexacerfont Phase 2
- Quetiapine fumarate Phase 3
- Sertraline Phase 3
- Tedatioxetine Phase 1
- Tiagabine hydrochloride Phase 3
Other linked drugs (4)
- Duloxetine hydrochloride
- Fluoxetine
- Norepinephrine
- Serotonin